The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?
Featured:
Sarita Rani JaiswalDuring the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Sarita Rani Jaiswal, Dharamshila Narayana Superspeciality Hospital, New Delhi, IN. We asked, Why can CTLA4Ig-primed sequential donor lymphocyte infusion (DLI) improve chronic GvHD and relapse-free survival (RFS) after allogeneic hematopoietic stem cell transplant (allo-HSCT)?
Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?
CTLA4Ig can block costimulation, and therefore activation, of T cells by binding to CD80 and CD86 on antigen-presenting cells. This effect is selective for T cells, as natural killer cells are resistant to CTLA4Ig-mediated anergy and in fact show an increased antitumor action. Sarita Rani Jaiswal's group has used this unique property of CTLA4Ig in the clinic to improve chronic GvHD.